Lantern Pharma (LTRN) AI Stock Analysis

• Market Cap: $39.59M
• Dividend Yield: N/A
• Average Volume (3M): 51.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: N/A
• EPS Growth: 1.18%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 11,184,423
• 10 Day Avg. Volume: 47,166
• 30 Day Avg. Volume: 51,551
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.93
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -581.91
• Enterprise Value/Ebitda: -1.80
• 1Y Price Target: $25.00
• Price Target Upside: 727.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.97
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $3.50 ▲(15.89% Upside)

The score is held back primarily by weak financial performance (no revenue, persistent losses, and significant cash burn), which elevates financing/runway risk. Offsetting this, the earnings call conveyed meaningful pipeline and regulatory progress plus RADR commercialization momentum. Technicals remain soft (below major moving averages), while valuation metrics are constrained by negative earnings and no indicated dividend.

Positive Factors

AI platform commercialization (RADR)

RADR's stated commercial readiness indicates Lantern can monetize its AI capabilities via licensing or services to biopharma, creating a recurring, scalable revenue pathway distinct from drug approvals. This structural capability can diversify cash sources and improve partner-driven trial economics over time.

Clinical validation of LP-184

Meeting Phase Ia endpoints with a 48% clinical benefit in evaluable patients materially de-risks LP-184's development path. Durable safety and activity signals, especially in biomarker-enriched populations, support efficient Phase 1b/2 designs and strengthen potential partner interest and regulatory discussions over the next several quarters.

Low financial leverage

Extremely low debt reduces near-term solvency and interest-service burdens, preserving flexibility to pursue R&D and partnerships. For a clinical-stage biotech, minimal leverage lowers bankruptcy risk and gives management optionality to raise non-debt capital or structure collaborations without looming debt covenants.

Negative Factors

Persistent negative cash flow

Sustained negative operating cash flow at material levels exhausts liquidity and forces continual fundraising, which can dilute shareholders and distract management. Over a 2–6 month horizon this burn constrains the ability to scale concurrent trials or commercialize RADR without new capital or non-dilutive partnerships.

Pre-revenue business model

Being pre-revenue means Lantern cannot self-fund development or commercialization from product receipts, leaving operations dependent on capital markets or deals. This structural reliance increases execution risk, limits internal reinvestment capacity, and heightens sensitivity to financing conditions over the medium term.

Near-term funding/runway risk

Management's admission of material additional funding needs, combined with reported cash (~$12.4M runway into Q3 2026), creates a clear structural risk: required capital raises or partnership deals could cause dilution or alter program timing, potentially delaying trials or commercialization efforts if markets or partners are unfavorable.

Lantern Pharma Business Overview & Revenue Model

Company Description

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

How the Company Makes Money

Lantern Pharma generates revenue primarily through the development and commercialization of its drug candidates. The company uses its proprietary RADR platform to identify biomarkers and genetic signatures that can predict patient response to its drug candidates, thereby reducing time and cost associated with drug development. Revenue streams include out-licensing partnerships, collaborations with pharmaceutical companies, and potentially, future sales of approved drugs. These partnerships often involve milestone payments, royalties, and shared development costs, which are significant contributors to the company's earnings. As Lantern Pharma advances its drug pipeline and secures additional partnerships, these factors are expected to drive financial growth.

Lantern Pharma Financial Statement Overview

Summary

Lantern Pharma faces significant financial challenges, with zero revenue and increasing operational losses. Despite a strong balance sheet with low debt, the negative cash flow situation raises concerns about long-term viability and the need for additional financing.

Income Statement

Lantern Pharma has consistently reported zero revenue, indicating a pre-revenue stage or significant challenges in generating sales. The company's net losses have increased substantially over the years, reflecting mounting operational challenges. The EBIT and EBITDA margins are negative due to high operational expenses without corresponding revenue, undermining profitability prospects.

Balance Sheet

The company maintains a strong equity position relative to its assets, with a high equity ratio, reflecting financial stability. The debt-to-equity ratio is low, indicating minimal reliance on debt financing, which reduces financial risk. However, the consistent increase in liabilities and decreasing cash reserves could affect future liquidity and operational capacity.

Cash Flow

Lantern Pharma exhibits negative operating and free cash flows, indicating cash burn without revenue inflow. Despite substantial financing inflows in prior years, the inability to generate positive cash flows from operations is concerning. The lack of free cash flow growth highlights potential sustainability challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-59.90K	0.00	-174.84K	0.00	0.00	0.00
EBITDA	-19.41M	-22.20M	-15.79M	-14.42M	-12.58M	-5.90M
Net Income	-18.92M	-20.78M	-15.96M	-14.26M	-12.36M	-5.91M
Balance Sheet
Total Assets	13.63M	25.57M	43.65M	58.84M	73.95M	20.36M
Cash, Cash Equivalents and Short-Term Investments	12.36M	24.01M	41.30M	55.20M	70.73M	19.23M
Total Debt	93.95K	243.66K	234.47K	52.89K	204.95K	108.50K
Total Liabilities	4.04M	4.38M	2.74M	2.80M	2.38M	660.84K
Stockholders Equity	9.59M	21.19M	40.91M	56.04M	71.57M	19.70M
Cash Flow
Free Cash Flow	-16.86M	-17.83M	-14.37M	-12.80M	-10.61M	-5.67M
Operating Cash Flow	-16.86M	-17.81M	-14.35M	-12.77M	-10.59M	-5.65M
Investing Cash Flow	16.21M	3.37M	-930.21K	179.27K	-19.53M	-16.14K
Financing Cash Flow	971.78K	66.71K	-500.00K	-2.18M	63.42M	23.66M

Lantern Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.02
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LTRN, the sentiment is Positive. The current price of 3.02 is below the 20-day moving average (MA) of 3.34, below the 50-day MA of 3.45, and below the 200-day MA of 3.74, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 52.80 is Neutral, neither overbought nor oversold. The STOCH value of 74.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LTRN.

Lantern Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LTRN	52 Neutral	$39.59M	-2.00	-104.58%	―	―	1.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNXT	51 Neutral	$38.85M	-2.90	-146.61%	―	―	37.89%
SKYE	48 Neutral	$32.70M	-0.75	-94.31%	―	―	-53.18%
BCAB	45 Neutral	$20.01M	-0.28	―	―	-100.00%	32.37%
MAIA	44 Neutral	$61.10M	-2.14	-2691.06%	―	―	44.50%
MDCX	43 Neutral	$36.42M	-0.66	-2237.54%	―	―	-55.95%

Lantern Pharma Corporate Events

Lantern Pharma Achieves Key Milestones in Q3 2025

Lantern Pharma reported its third quarter 2025 financial results and business updates, highlighting significant progress in clinical validation, regulatory advancements, and strategic momentum. The company achieved all primary endpoints in its LP-184 Phase 1a clinical trial, showing a 48% clinical benefit rate in cancer patients, and received FDA guidance for its pediatric CNS cancer trial. The AI platform’s commercial readiness was demonstrated, and disciplined capital management was maintained, positioning Lantern Pharma for future growth in oncology indications.

The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.